{"id":"W2556475996","doi":"10.1182/blood.v110.11.411.411","title":"Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carfilzomib; Proteasome inhibitor; Bortezomib; Medicine; Dosing; Pharmacology; Multiple myeloma; Mantle cell lymphoma; Tolerability; Proteasome; Internal medicine; Lymphoma; Adverse effect; Chemistry; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005739373,0.0001743515,0.0002844398,0.00005605643,0.0000534681,0.00000827666,0.0002233702,0.0001585403,0.000007848284],"category_scores_gemma":[0.000246018,0.0001370273,0.0001291227,0.000211785,0.0002333932,0.000006338073,0.0001685739,0.000133275,0.00000134695],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000176726,"about_ca_system_score_gemma":0.0001325636,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006010803,"about_ca_topic_score_gemma":0.00005571933,"domain_scores_codex":[0.9987186,0.0001465767,0.0003481073,0.0003013646,0.0001791763,0.0003061281],"domain_scores_gemma":[0.9991264,0.00004007826,0.000309447,0.0003647189,0.0001012035,0.0000581896],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000197463,0.001919713,0.00463321,0.0001128088,0.00003808974,0.00001949275,0.0002473599,0.000001049586,0.9923594,0.00005946601,0.00004018582,0.0003717362],"study_design_scores_gemma":[0.002888342,0.0007378412,0.003059396,0.0001446234,0.00003306502,0.00004221567,0.0001599175,0.000003738739,0.9924229,0.00003258201,0.0003183598,0.0001569957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973429,0.0006085944,0.0001896622,0.00004943544,0.0001099642,0.0007071214,0.0000858467,0.00001099407,0.0008954997],"genre_scores_gemma":[0.9993829,0.00001361415,0.0003822725,0.00005401919,0.00006722486,0.00002420991,0.00001006464,0.0000155361,0.00005019304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002690879,"threshold_uncertainty_score":0.5587811,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01962206881790056,"score_gpt":0.259396809851684,"score_spread":0.2397747410337834,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}